| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 148 | 2023 | 15694 | 2.950 |
Why?
|
| Mastectomy, Segmental | 37 | 2021 | 1026 | 1.910 |
Why?
|
| Carcinoma, Ductal, Breast | 22 | 2018 | 1216 | 1.440 |
Why?
|
| Neoplasm Recurrence, Local | 64 | 2021 | 10035 | 1.210 |
Why?
|
| Mastectomy | 41 | 2020 | 1534 | 1.120 |
Why?
|
| Brachial Plexus | 1 | 2022 | 45 | 0.850 |
Why?
|
| Carcinoma, Lobular | 11 | 2018 | 611 | 0.840 |
Why?
|
| Radiotherapy Dosage | 31 | 2018 | 3842 | 0.780 |
Why?
|
| Patient Positioning | 2 | 2015 | 195 | 0.760 |
Why?
|
| Radiotherapy, Conformal | 6 | 2019 | 902 | 0.740 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 16 | 2015 | 2370 | 0.690 |
Why?
|
| Skin | 4 | 2014 | 1259 | 0.680 |
Why?
|
| Lymphatic Metastasis | 40 | 2019 | 4844 | 0.660 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 8 | 2021 | 674 | 0.650 |
Why?
|
| Proton Therapy | 6 | 2020 | 1577 | 0.610 |
Why?
|
| Breast | 10 | 2021 | 1344 | 0.610 |
Why?
|
| Radiotherapy, Adjuvant | 34 | 2021 | 2231 | 0.590 |
Why?
|
| Photons | 4 | 2014 | 507 | 0.540 |
Why?
|
| Chemotherapy, Adjuvant | 42 | 2019 | 3890 | 0.510 |
Why?
|
| Radiation Injuries | 8 | 2018 | 1411 | 0.490 |
Why?
|
| Brachytherapy | 5 | 2018 | 977 | 0.470 |
Why?
|
| Female | 147 | 2023 | 141928 | 0.470 |
Why?
|
| Lymph Node Excision | 19 | 2023 | 1959 | 0.430 |
Why?
|
| Breast Cancer Lymphedema | 2 | 2023 | 38 | 0.430 |
Why?
|
| Mastectomy, Modified Radical | 6 | 2010 | 70 | 0.410 |
Why?
|
| Combined Modality Therapy | 47 | 2019 | 8865 | 0.410 |
Why?
|
| Lymphedema | 4 | 2023 | 239 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 35 | 2014 | 15862 | 0.390 |
Why?
|
| Neoplasm Staging | 35 | 2019 | 13658 | 0.390 |
Why?
|
| Neoadjuvant Therapy | 23 | 2015 | 4975 | 0.380 |
Why?
|
| Lymphatic Irradiation | 6 | 2009 | 133 | 0.380 |
Why?
|
| Humans | 160 | 2023 | 261506 | 0.350 |
Why?
|
| Middle Aged | 103 | 2021 | 86204 | 0.340 |
Why?
|
| Lymph Nodes | 15 | 2015 | 2967 | 0.330 |
Why?
|
| Doxorubicin | 22 | 2011 | 3005 | 0.330 |
Why?
|
| Mastectomy, Radical | 4 | 2005 | 39 | 0.330 |
Why?
|
| Adult | 97 | 2021 | 77950 | 0.330 |
Why?
|
| Mammaplasty | 8 | 2017 | 780 | 0.330 |
Why?
|
| Mammography | 9 | 2015 | 1010 | 0.320 |
Why?
|
| Monte Carlo Method | 2 | 2010 | 671 | 0.300 |
Why?
|
| Retrospective Studies | 65 | 2021 | 37905 | 0.300 |
Why?
|
| Aged | 75 | 2021 | 70117 | 0.290 |
Why?
|
| Radiotherapy | 11 | 2017 | 1824 | 0.290 |
Why?
|
| Axilla | 14 | 2015 | 902 | 0.290 |
Why?
|
| Iridium Radioisotopes | 1 | 2006 | 56 | 0.280 |
Why?
|
| Electrons | 3 | 2010 | 168 | 0.280 |
Why?
|
| Phantoms, Imaging | 4 | 2006 | 1271 | 0.280 |
Why?
|
| Follow-Up Studies | 28 | 2020 | 14889 | 0.270 |
Why?
|
| Disease-Free Survival | 31 | 2017 | 10001 | 0.250 |
Why?
|
| Ultrasonography, Mammary | 4 | 2015 | 380 | 0.240 |
Why?
|
| Carcinoma in Situ | 4 | 2005 | 487 | 0.220 |
Why?
|
| Radiation Oncology | 4 | 2020 | 529 | 0.210 |
Why?
|
| Treatment Outcome | 43 | 2021 | 32848 | 0.210 |
Why?
|
| Receptors, Progesterone | 3 | 2012 | 1392 | 0.200 |
Why?
|
| Lymphatic Vessels | 1 | 2022 | 143 | 0.200 |
Why?
|
| Computer Simulation | 1 | 2006 | 1529 | 0.190 |
Why?
|
| Receptors, Estrogen | 5 | 2012 | 2086 | 0.190 |
Why?
|
| Radiotherapy, High-Energy | 3 | 1998 | 295 | 0.190 |
Why?
|
| Paclitaxel | 6 | 2011 | 1996 | 0.180 |
Why?
|
| Duodenal Ulcer | 1 | 2000 | 113 | 0.180 |
Why?
|
| Radiography | 6 | 2010 | 1904 | 0.180 |
Why?
|
| Germ-Line Mutation | 2 | 2021 | 1046 | 0.170 |
Why?
|
| Prospective Studies | 20 | 2023 | 12873 | 0.170 |
Why?
|
| Radiodermatitis | 2 | 2011 | 75 | 0.170 |
Why?
|
| Cosmetics | 1 | 2018 | 17 | 0.170 |
Why?
|
| Clavicle | 5 | 2010 | 65 | 0.160 |
Why?
|
| Sternum | 1 | 2019 | 100 | 0.160 |
Why?
|
| Tissue Expansion | 2 | 2017 | 71 | 0.160 |
Why?
|
| Survival Analysis | 25 | 2009 | 9180 | 0.160 |
Why?
|
| Movement | 3 | 2011 | 556 | 0.160 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2018 | 2104 | 0.160 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 799 | 0.160 |
Why?
|
| Survival Rate | 15 | 2017 | 12221 | 0.150 |
Why?
|
| Surgical Flaps | 6 | 2007 | 927 | 0.150 |
Why?
|
| Multivariate Analysis | 11 | 2015 | 4298 | 0.150 |
Why?
|
| Margins of Excision | 1 | 2019 | 285 | 0.150 |
Why?
|
| Radiation Dosage | 5 | 2006 | 1014 | 0.150 |
Why?
|
| Sentinel Lymph Node Biopsy | 5 | 2014 | 1415 | 0.150 |
Why?
|
| Aged, 80 and over | 25 | 2021 | 29902 | 0.140 |
Why?
|
| Prognosis | 20 | 2018 | 21713 | 0.140 |
Why?
|
| Treatment Failure | 6 | 2011 | 1391 | 0.140 |
Why?
|
| Capecitabine | 1 | 2017 | 388 | 0.140 |
Why?
|
| Reimbursement Mechanisms | 1 | 2016 | 78 | 0.130 |
Why?
|
| Analysis of Variance | 11 | 2010 | 2307 | 0.130 |
Why?
|
| Supine Position | 1 | 2015 | 46 | 0.130 |
Why?
|
| Receptor, ErbB-2 | 3 | 2012 | 2518 | 0.130 |
Why?
|
| Time Factors | 16 | 2021 | 12926 | 0.130 |
Why?
|
| Risk Assessment | 11 | 2021 | 6869 | 0.130 |
Why?
|
| Fluorouracil | 11 | 2011 | 1944 | 0.130 |
Why?
|
| Fetus | 1 | 1998 | 601 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2010 | 726 | 0.130 |
Why?
|
| Mediastinal Neoplasms | 1 | 2019 | 423 | 0.130 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 792 | 0.120 |
Why?
|
| Body Mass Index | 4 | 2010 | 2203 | 0.120 |
Why?
|
| Cyclophosphamide | 12 | 2011 | 3001 | 0.120 |
Why?
|
| Communication | 1 | 2020 | 876 | 0.120 |
Why?
|
| Medicare | 2 | 2016 | 860 | 0.110 |
Why?
|
| Epothilones | 1 | 2013 | 54 | 0.110 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 2009 | 222 | 0.110 |
Why?
|
| Watchful Waiting | 1 | 2015 | 289 | 0.110 |
Why?
|
| Exercise | 1 | 2000 | 1183 | 0.110 |
Why?
|
| Coronary Vessels | 2 | 2011 | 665 | 0.110 |
Why?
|
| Emollients | 1 | 2011 | 12 | 0.110 |
Why?
|
| Petrolatum | 1 | 2011 | 11 | 0.100 |
Why?
|
| Prostheses and Implants | 2 | 2007 | 295 | 0.100 |
Why?
|
| Age Factors | 4 | 2011 | 5377 | 0.100 |
Why?
|
| Scattering, Radiation | 2 | 2010 | 316 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2000 | 551 | 0.100 |
Why?
|
| Risk Factors | 17 | 2021 | 17523 | 0.100 |
Why?
|
| Brain Neoplasms | 3 | 2020 | 4849 | 0.100 |
Why?
|
| Melanoma | 5 | 2002 | 5317 | 0.100 |
Why?
|
| Radiation-Protective Agents | 1 | 2011 | 128 | 0.100 |
Why?
|
| Inhalation | 1 | 2011 | 42 | 0.100 |
Why?
|
| Algorithms | 3 | 2014 | 3890 | 0.100 |
Why?
|
| Canada | 3 | 2021 | 429 | 0.100 |
Why?
|
| Drug Administration Schedule | 8 | 2017 | 3472 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 1299 | 0.100 |
Why?
|
| Mammary Arteries | 2 | 2005 | 64 | 0.090 |
Why?
|
| Hyaluronic Acid | 1 | 2011 | 168 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2020 | 6207 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 6 | 2017 | 3981 | 0.090 |
Why?
|
| Patient Selection | 4 | 2008 | 2055 | 0.090 |
Why?
|
| Myocardial Contraction | 1 | 2011 | 291 | 0.090 |
Why?
|
| Odds Ratio | 5 | 2015 | 2316 | 0.090 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2017 | 1215 | 0.080 |
Why?
|
| Tamoxifen | 5 | 2006 | 876 | 0.080 |
Why?
|
| BRCA1 Protein | 2 | 2021 | 493 | 0.080 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2011 | 749 | 0.080 |
Why?
|
| Cohort Studies | 9 | 2021 | 9244 | 0.080 |
Why?
|
| Coronary Angiography | 1 | 2011 | 598 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2005 | 840 | 0.080 |
Why?
|
| Respiration | 1 | 2010 | 447 | 0.080 |
Why?
|
| Skin Neoplasms | 4 | 2009 | 4654 | 0.080 |
Why?
|
| Tumor Burden | 2 | 2011 | 1987 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2014 | 1171 | 0.080 |
Why?
|
| Nomograms | 1 | 2010 | 313 | 0.080 |
Why?
|
| Radiometry | 1 | 2013 | 980 | 0.070 |
Why?
|
| Heart | 2 | 2011 | 1223 | 0.070 |
Why?
|
| Regression Analysis | 5 | 2014 | 1546 | 0.070 |
Why?
|
| Proportional Hazards Models | 7 | 2020 | 4988 | 0.070 |
Why?
|
| Neoplasm Proteins | 3 | 2010 | 3230 | 0.070 |
Why?
|
| Chi-Square Distribution | 3 | 2015 | 1323 | 0.070 |
Why?
|
| Carotid Arteries | 1 | 2008 | 240 | 0.070 |
Why?
|
| Postoperative Period | 3 | 2004 | 665 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2002 | 852 | 0.070 |
Why?
|
| Carotid Stenosis | 1 | 2008 | 176 | 0.070 |
Why?
|
| Taxoids | 1 | 2010 | 967 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 2576 | 0.070 |
Why?
|
| Hypothyroidism | 1 | 2008 | 204 | 0.070 |
Why?
|
| Salvage Therapy | 2 | 2005 | 2054 | 0.070 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 361 | 0.070 |
Why?
|
| United States | 8 | 2021 | 15433 | 0.070 |
Why?
|
| Remission Induction | 2 | 2009 | 3569 | 0.070 |
Why?
|
| Thoracic Arteries | 1 | 2005 | 10 | 0.060 |
Why?
|
| Texas | 7 | 2020 | 6311 | 0.060 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2017 | 85 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 6009 | 0.060 |
Why?
|
| Catheterization | 2 | 2004 | 410 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2014 | 7551 | 0.060 |
Why?
|
| Seroma | 2 | 2018 | 79 | 0.060 |
Why?
|
| Adenocarcinoma | 4 | 2008 | 7789 | 0.060 |
Why?
|
| Ataxia Telangiectasia | 1 | 2004 | 62 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1945 | 0.060 |
Why?
|
| Positron-Emission Tomography | 2 | 2009 | 2173 | 0.060 |
Why?
|
| Carcinoma, Ductal | 1 | 2004 | 145 | 0.060 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2004 | 126 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 2 | 2003 | 1350 | 0.050 |
Why?
|
| Antineoplastic Agents | 7 | 2012 | 14289 | 0.050 |
Why?
|
| Radiology | 1 | 2008 | 434 | 0.050 |
Why?
|
| Ultrasonography, Interventional | 1 | 2005 | 429 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 644 | 0.050 |
Why?
|
| Logistic Models | 4 | 2015 | 3441 | 0.050 |
Why?
|
| Medical Records | 2 | 2020 | 415 | 0.050 |
Why?
|
| Quality of Life | 3 | 2023 | 4532 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2008 | 1335 | 0.050 |
Why?
|
| Professional Staff Committees | 1 | 2001 | 30 | 0.050 |
Why?
|
| Clinical Trials as Topic | 6 | 2010 | 3719 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2004 | 1163 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 3251 | 0.050 |
Why?
|
| Actuarial Analysis | 2 | 2002 | 159 | 0.050 |
Why?
|
| Edema | 2 | 2018 | 267 | 0.050 |
Why?
|
| Thoracic Neoplasms | 1 | 2003 | 337 | 0.050 |
Why?
|
| Stainless Steel | 1 | 1999 | 26 | 0.050 |
Why?
|
| Hospitals, University | 1 | 2020 | 209 | 0.050 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 1258 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2006 | 6550 | 0.050 |
Why?
|
| Body Image | 1 | 2021 | 141 | 0.040 |
Why?
|
| Observer Variation | 2 | 2014 | 671 | 0.040 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2004 | 502 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2023 | 294 | 0.040 |
Why?
|
| Confidence Intervals | 3 | 2006 | 756 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 335 | 0.040 |
Why?
|
| Genes, BRCA2 | 1 | 2021 | 309 | 0.040 |
Why?
|
| Adolescent | 9 | 2019 | 31252 | 0.040 |
Why?
|
| Lung | 1 | 2010 | 3151 | 0.040 |
Why?
|
| Neoplasm, Residual | 4 | 2011 | 1656 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2001 | 315 | 0.040 |
Why?
|
| Pneumonia | 1 | 2004 | 751 | 0.040 |
Why?
|
| Anus Neoplasms | 1 | 2002 | 411 | 0.040 |
Why?
|
| Risk | 2 | 2014 | 1972 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 291 | 0.040 |
Why?
|
| Patient Satisfaction | 2 | 2020 | 915 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 5539 | 0.040 |
Why?
|
| Tissue Expansion Devices | 1 | 2017 | 62 | 0.040 |
Why?
|
| Radiation Protection | 1 | 1998 | 205 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 160 | 0.040 |
Why?
|
| Young Adult | 5 | 2019 | 21445 | 0.040 |
Why?
|
| Family | 1 | 2000 | 736 | 0.040 |
Why?
|
| Clinical Coding | 1 | 2016 | 28 | 0.030 |
Why?
|
| Fat Necrosis | 2 | 2007 | 63 | 0.030 |
Why?
|
| Postoperative Care | 2 | 2014 | 739 | 0.030 |
Why?
|
| Nipples | 2 | 2007 | 132 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 1998 | 297 | 0.030 |
Why?
|
| SEER Program | 2 | 2010 | 1000 | 0.030 |
Why?
|
| Postoperative Complications | 4 | 2007 | 5542 | 0.030 |
Why?
|
| Biopsy, Needle | 2 | 2015 | 1363 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 306 | 0.030 |
Why?
|
| Sex Factors | 1 | 2000 | 2139 | 0.030 |
Why?
|
| Fibrosis | 1 | 2018 | 793 | 0.030 |
Why?
|
| Mastectomy, Simple | 2 | 1993 | 58 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1999 | 1064 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2017 | 1529 | 0.030 |
Why?
|
| Rectal Neoplasms | 1 | 2002 | 1202 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 1374 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2010 | 4892 | 0.030 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1995 | 142 | 0.030 |
Why?
|
| Physical Examination | 1 | 2015 | 299 | 0.030 |
Why?
|
| Prone Position | 1 | 2013 | 56 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 7702 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2009 | 2594 | 0.030 |
Why?
|
| Probability | 2 | 2004 | 866 | 0.030 |
Why?
|
| Esthetics | 2 | 2007 | 189 | 0.030 |
Why?
|
| Breast Implants | 1 | 2017 | 391 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2004 | 5178 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 672 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 945 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2020 | 1423 | 0.030 |
Why?
|
| Etoposide | 2 | 2006 | 870 | 0.030 |
Why?
|
| Pregnancy | 2 | 2009 | 7573 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2011 | 257 | 0.020 |
Why?
|
| Carcinoma | 1 | 2003 | 2578 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2008 | 925 | 0.020 |
Why?
|
| Palliative Care | 2 | 2019 | 2037 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 4938 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2011 | 409 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Color | 2 | 2005 | 100 | 0.020 |
Why?
|
| Helicobacter pylori | 1 | 2000 | 1295 | 0.020 |
Why?
|
| British Columbia | 1 | 2010 | 24 | 0.020 |
Why?
|
| Helicobacter Infections | 1 | 2000 | 1216 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 690 | 0.020 |
Why?
|
| Incidence | 3 | 2005 | 5673 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 4320 | 0.020 |
Why?
|
| Pain | 1 | 2018 | 1658 | 0.020 |
Why?
|
| Consensus | 1 | 2014 | 978 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2004 | 430 | 0.020 |
Why?
|
| Forecasting | 2 | 2004 | 694 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2012 | 696 | 0.020 |
Why?
|
| Neoplasm Metastasis | 3 | 2009 | 5112 | 0.020 |
Why?
|
| Disease Management | 1 | 2015 | 1052 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2010 | 342 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2000 | 1833 | 0.020 |
Why?
|
| Premenopause | 1 | 2009 | 131 | 0.020 |
Why?
|
| Registries | 2 | 2008 | 2170 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 2006 | 1914 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 1742 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 5767 | 0.020 |
Why?
|
| Efficiency | 1 | 2008 | 99 | 0.020 |
Why?
|
| Ultrasonics | 1 | 2008 | 69 | 0.020 |
Why?
|
| Prednisone | 2 | 2001 | 984 | 0.020 |
Why?
|
| Postmenopause | 1 | 2009 | 378 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2008 | 276 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2010 | 627 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 1183 | 0.020 |
Why?
|
| Methotrexate | 1 | 2010 | 999 | 0.020 |
Why?
|
| Thermoluminescent Dosimetry | 1 | 2006 | 77 | 0.020 |
Why?
|
| Neutropenia | 2 | 2002 | 968 | 0.020 |
Why?
|
| Vincristine | 2 | 2001 | 1511 | 0.020 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2009 | 388 | 0.020 |
Why?
|
| Male | 6 | 2019 | 123000 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1995 | 1429 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 1863 | 0.020 |
Why?
|
| Rectus Abdominis | 1 | 2006 | 100 | 0.020 |
Why?
|
| Cisplatin | 2 | 2006 | 2432 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 4971 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2006 | 6100 | 0.020 |
Why?
|
| Calibration | 1 | 2005 | 337 | 0.020 |
Why?
|
| Overweight | 1 | 2007 | 484 | 0.010 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 1946 | 0.010 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2004 | 88 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 5437 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2004 | 1823 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 698 | 0.010 |
Why?
|
| Abdominal Neoplasms | 1 | 2005 | 231 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 5687 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2005 | 371 | 0.010 |
Why?
|
| Cicatrix | 1 | 2005 | 208 | 0.010 |
Why?
|
| Cell Cycle Proteins | 2 | 2004 | 2045 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 2004 | 259 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 726 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 1301 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 445 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 1544 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2007 | 1226 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 15179 | 0.010 |
Why?
|
| Arm | 1 | 2002 | 147 | 0.010 |
Why?
|
| Organizational Objectives | 1 | 2001 | 61 | 0.010 |
Why?
|
| Radiation Tolerance | 1 | 2004 | 629 | 0.010 |
Why?
|
| Recurrence | 2 | 2002 | 4758 | 0.010 |
Why?
|
| Equipment Design | 1 | 2004 | 1204 | 0.010 |
Why?
|
| Arteries | 1 | 2001 | 274 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 980 | 0.010 |
Why?
|
| Prevalence | 1 | 2008 | 3260 | 0.010 |
Why?
|
| Melanoma, Amelanotic | 1 | 1998 | 9 | 0.010 |
Why?
|
| Fever | 1 | 2002 | 497 | 0.010 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 4821 | 0.010 |
Why?
|
| Vinblastine | 1 | 1998 | 453 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 4917 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 2403 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2001 | 544 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1998 | 310 | 0.010 |
Why?
|
| BRCA2 Protein | 1 | 1999 | 358 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 6089 | 0.010 |
Why?
|
| Dacarbazine | 1 | 1998 | 485 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 4744 | 0.010 |
Why?
|
| Genes, BRCA1 | 1 | 1999 | 387 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2004 | 2086 | 0.010 |
Why?
|
| Smoking | 1 | 2005 | 2440 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1998 | 842 | 0.010 |
Why?
|
| Obesity | 1 | 2007 | 2884 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1998 | 889 | 0.010 |
Why?
|
| Genes, p53 | 1 | 1999 | 1090 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1999 | 2292 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1999 | 1910 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 2927 | 0.010 |
Why?
|
| Decision Making | 1 | 2000 | 1287 | 0.010 |
Why?
|
| Biopsy | 1 | 2000 | 3443 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 1999 | 1678 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2010 | 10331 | 0.010 |
Why?
|
| Proteins | 1 | 1999 | 1963 | 0.010 |
Why?
|
| Transcription Factors | 1 | 1999 | 5270 | 0.000 |
Why?
|